RT Journal Article
SR Electronic
T1 Effects of ghrelin on the dyspnea pattern in cachectic COPD: Exploratory analysis of a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P2499
VO 42
IS Suppl 57
A1 Keisuke Miki
A1 Ryoji Maekura
A1 Noritoshi Nagaya
A1 Seigo Kitada
A1 Mari Miki
A1 Kenji Yoshimura
A1 Hideki Matsui
A1 Akitoshi Satomi
A1 HIsako Hashimoto
A1 Masahide Mori
A1 Kenji Kangawa
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P2499.abstract
AB Background: The substudy of the ghrelin treatment, multicenter, randomized, double-blind, placebo-controlled trial demonstrated that ghrelin administration was associated with improved exertional capacity and improvements in ventilatory-cardiac parameters in cachectic COPD patients. To clarify more precisely the dyspnea pattern during exercise, the data from the substudy were analyzed in an exploratory manner.Method: Of 20 cachectic COPD patients who were randomized to pulmonary rehabilitation with intravenous ghrelin (2 mg/kg, n = 10) or placebo (n = 10) twice daily for 3 weeks in the substudy, 17 patients (ghrelin = 9, placebo = 7) could be investigated for the dyspnea break-point on the dyspnea-ratio (%) of delta oxygen uptake (Vo2) (= peak minus resting Vo2) curve.Results: No treatment effect compared with placebo was found in the Borg scale at the dyspnea break-point, or in the plasma lactate level at the lactate break-point. However, a significant treatment effect by ghrelin administration in the percentage of delta Vo2 at the dyspnea break-point (treatment effect -18%, 95% CI -35.9 to -0.0; p = 0.049) was obtained. Similarly, the percentage of delta Vo2 at the lactate break-point was significantly shifted to the early exercise phase compared with placebo (treatment effect -19%, 95% CI -34.1 to -4.2; p = 0.017).Conclusions: Cachectic patients with COPD benefited from ghrelin treatment in terms of shifts to the early exercise phase in the dyspnea break-point and in the lactate threshold during a standardized exercise program.Trial Registration: UMIN, number C000000061.